ADC Therapeutics SA
ADCT
$3.10
-$0.01-0.32%
NYSE
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -18.21% | 36.21% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -18.21% | 36.21% | |||
| Cost of Revenue | -59.44% | -98.13% | |||
| Gross Profit | -14.16% | 122.49% | |||
| SG&A Expenses | -7.50% | -1.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.11% | 4.36% | |||
| Operating Income | -9.11% | 12.25% | |||
| Income Before Tax | -44.11% | -23.80% | |||
| Income Tax Expenses | 660.00% | 151.40% | |||
| Earnings from Continuing Operations | -46.74% | -25.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -46.74% | -25.63% | |||
| EBIT | -9.11% | 12.25% | |||
| EBITDA | -9.15% | 12.38% | |||
| EPS Basic | -38.29% | -23.53% | |||
| Normalized Basic EPS | -3.70% | -21.73% | |||
| EPS Diluted | -38.29% | -23.53% | |||
| Normalized Diluted EPS | -3.70% | -21.73% | |||
| Average Basic Shares Outstanding | 6.10% | 1.71% | |||
| Average Diluted Shares Outstanding | 6.10% | 1.71% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||